ArticleNeurology(R) neuroimmunology & neuroinflammation2026
MIF Tautomerase Inhibition Protects Neurons From Immune-Mediated Cell Death.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMultiple sclerosis (MS) is characterized by peripheral immune cell infiltration into the central nervous system (CNS) and associated reactive gliosis, demyelination, and neuroaxonal degeneration. Existing therapies broadly target adaptive immune cells and treat acute inflammation but are not effective in halting chronic neurodegeneration that occurs in progressive MS. High-efficacy precision therapies that target pathways in the CNS known to contribute to MS pathophysiology are lacking. Several MS studies have identified prominent dysregulation of macrophage migration inhibitory factor (MIF), a multifunctional protein with both cytokine and enzyme activity, in inflammatory diseases. MIF is elevated in the CSF of people with MS and MIF gene variants have been linked with progressive MS, but its precise contributions to the pathophysiologic underpinnings of MS remain unclear. MIF has extracellular signaling capacity through CD74. MIF also has 2 discrete and endogenous enzymatic functions as a tautomerase and nuclease.
methodsWe used a MIF transgenic mouse line with a point mutation in the tautomerase domain (MIF-P2G) to dissect MIF's non-nuclease function during inflammation. We also utilized flow cytometry and immunohistochemistry to characterize the cellular and molecular mechanisms by which MIF tautomerase contributes to pathophysiology in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.
resultsWe show that MIF tautomerase contributes to immune cell infiltration, glial cell proliferation, and neuroaxonal degeneration in EAE. MIF tautomerase-deficient EAE mice have reduced paralysis scores and less neuroaxonal pathology throughout the optic nerve and lumbar spinal cord. Furthermore, we show that MIF-P2G mutated mice have less peripheral immune cell trafficking and downstream reactive gliosis, neuroinflammation, and neurodegeneration during EAE. DISCUSSION: Together, this work elucidates the role of MIF's tautomerase domain in contributing to peripheral immune-mediated neurodegeneration in the context of neuroinflammatory diseases such as MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.